1Ripamonti C, Brueva E. Palliative management of maligmant Sawel ob- struction[ J]. Int J Gynecol Cancer,2002, 12 : 135 - 143.
2孙传兴.f临床疾病诊断依据治愈好转标准[M].第2版.北京:人民军医出版社.1998:357.
3Nellgard P, Bojo L, Cassuto J. hnportance of vasoactive intestinalpeptide and somatostatin for fluid iosses in small - bowel obstruction[ J]. Scand J Gastroenterol, 1995,30:464 - 469.
4Yamaner S, Bugra D, Muslumanoglu M,et al. Effects of octreotide on heal- ing of intestinal anastomosis following small bowel obstruction in rats [ J ]. Dis Colon Rectum, 1995,38 : 308 - 312.
5Aldemir M, Kokoglu O F, Geyik M F,et al. Effects ofoctreotide acetate and Saccharomyces boulardii on bacterial translocation in an experimen- talintestinal loop obstruction model of rats[ J]. Tohoku J Exp Med,2002, 198:1 -9.
10Samuels BL.Management of recurrent dosmoid tumor after surgery and radiation : role of cytotoxic and non cytotoxic therapies [J].Surg Oncol,1999,8:191- 196.
1YU S Y, WANG J J, WANG J W, et al. Consensus of experts on the management of malignant bowel ob- struction in patients with advanced cancer[J]. Chinese Journal of Oncology, 2007, 29 : 637-- 640.
2SELBY D, WRIGHT F, STILOS K, et al. Room for improvement A quality-of-life assessment in patients with malignant bowel obstruction [J]. Palliat Med, 2010, 24:38--45.
3RIPAMONTI C I, EASSON A M, GERDES H. Man- agement of malignant bowel obstruction[J]. Eur J Cancer, 2008, 44 : 1105-- 1115.
